With ‘bold experiment’ in drug pricing, Arcutis aims to stand out in plaque psoriasis
FDA approval of a new Arcutis Biotherapeutics drug for plaque psoriasis enables the company to roll out a strategy it believes will win over both payers and patients—lower prices. Arcutis set an $825 wholesale price for each tube of its topical drug, roflumilast, which will be marketed under the brand name “Zoryve.” By comparison, Dermavant … Read more